As biopharma deal values climb, industry M&As are at a five-year low, not yet showing the pickup in 2022 that some analysts expected. BioWorld has recorded 330 deals, including licensings, joint ventures and collaborations, valued at $44.4 billion so far in 2022. That is a 41% increase in volume and a 31% increase in value over the same time frame last year.
From every perspective, the number of biopharma deals with nonprofit or government entities, as well as industry grants, are significantly below last year, and efforts focused on the COVID-19 pandemic have dropped as well.
A total of seven new molecular entities (NME) have been approved by the U.S. FDA this year, while another seven therapies received dreaded complete response letters from the agency. Out of 9 FDA approvals in February, including two BLAs, three NDAs, three supplemental applications, and one abbreviated NDA, were three NME clearances.
PERTH, Australia – Australia should be at the front of the line among developed nations when it comes to innovative drugs and devices, but health policies must evolve to respond to changes in technology and global trends, Johnson & Johnson (J&J) said. Although Australia’s health policy has served the country well, tensions in the system are becoming seismic shifts that mirror international trends, J&J said in a recent report on Australia’s health system.
In what is undeniably one of the busiest years for governmental agencies across the globe, 2021 churned out a 12% increase in regulatory news over the previous record year of 2020.
While most of the 30 stocks that comprise BioWorld’s Drug Developers Index (BDDI) are trading down for the year, the three showing the most upward movement in 2021 include a company at the forefront of COVID-19 vaccine development, an RNAi therapeutics firm that became a multibillion-dollar acquisition target, and a neurological disease company with one marketed product.
With a few weeks left in the year, the biopharma industry has raised a total of $116.18 billion through 1,506 transactions, both of which are second only to 2020.
With a growing number of deals worth $1 billion or more, 2021 values are slowly inching past 2020’s record year, as mergers and acquisitions also move higher, indicating a potentially stronger second half of the year.
When the SARS-CoV-2 virus first emerged in the U.S., the knee-jerk reaction by biopharma researchers was to make the best vaccines and therapeutics possible and to do so quickly.
